Articles that tag ARWR but are mainly about other companies.
Arrowhead is developing Zodasiran (ARO-ANG3), an investigational RNA interference therapy targeting ANGPTL3. This emerging therapy aligns with the market's shift toward long-acting, receptor-independent treatments with significant growth potential.
Late-stage siRNA programs are increasing manufacturing requirements, positioning the company to benefit from the fastest-growing oligonucleotide segment.
ARO-C3 is in development as an emerging complement inhibitor, contributing to the company's pipeline in this growing therapeutic area.
ARO-C3 in development as RNA interference therapy targeting complement C3 for complement-mediated kidney disorders, representing innovative therapeutic approach.
Mentioned as a competitive comparison for CTX310's LDL-C reduction efficacy. No direct positive or negative news; serves as a benchmark for CRISPR's pipeline performance.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
